Erika Vacchelli
Affiliations: | University Paris 11 |
Area:
Breast cancer, Signature, Non small cell lung cancer, Head and neck carcinoma, Immunogenic cell death, ECE1, PZP, Rs2241880, Rs3751143, Rs4986790, CancerGoogle:
"Erika Vacchelli"Parents
Sign in to add mentor| Guido Kroemer | grad student | 2014 | University Paris 11 | |
| (Immunogenetic determinants of chemotherapy response in cancer) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Le Naour J, Montégut L, Pan Y, et al. (2023) Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis. Oncoimmunology. 12: 2237354 |
| Carbonnier V, Le Naour J, Bachelot T, et al. (2023) Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer. Oncoimmunology. 12: 2189823 |
| Le Naour J, Sztupinszki Z, Carbonnier V, et al. (2022) A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients. Oncoimmunology. 11: 2059878 |
| Sztupinszki Z, Le Naour J, Vacchelli E, et al. (2021) A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. Oncoimmunology. 10: 1859064 |
| Petrazzuolo A, Le Naour J, Vacchelli E, et al. (2020) No impact of cancer and plague-relevant polymorphisms on COVID-19. Oncoimmunology. 9: 1857112 |
| Castoldi F, Humeau J, Martins I, et al. (2020) Autophagy-mediated metabolic effects of aspirin. Cell Death Discovery. 6: 129 |
| Le Naour J, Liu P, Zhao L, et al. (2020) A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discovery |
| Frega G, Wu Q, Le Naour J, et al. (2020) Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology. 9: 1796002 |
| Le Naour J, Galluzzi L, Zitvogel L, et al. (2020) Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 9: 1777625 |
| Le Naour J, Zitvogel L, Galluzzi L, et al. (2020) Trial watch: STING agonists in cancer therapy. Oncoimmunology. 9: 1777624 |